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Summary 
To extend the mammalian cell death pathway, we 
screened for further Bcl-2 interacting proteins. Both 
yeast two-hybrid screening and ;~ expression cloning 
identified a novel interacting protein, Bad, whose ho- 
mology to Bcl-2 is limited to the BH1 and BH2 domains. 
Bad selectively dimerized with Bcl-x, as well as Bcl-2, 
but not with Bax, Bcl-xs, Mcl-1, A1, or itself. Bad binds 
more strongly to Bcl-x, than Bcl-2 in mammalian cells, 
and it reversed the death repressor activity of Bcl-x,, 
but not that of Bcl-2. When Bad dimerized with Bcl-x,, 
Bax was displaced and apoptosis was restored. When 
approximately half of Bax was heterodimerized, death 
was inhibited. The susceptibility of a cell to a death 
signal is determined by these competing dimerizations 
in which levels of Bad influence the effectiveness of 
Bcl-2 versus Bcl-xL in repressing death. 
Introduction 
The development of multilineage organisms and the main- 
tenance of homeostasis within tissues both require a tightly 
regulated cell death pathway. However, the capacity of an 
individual cell to execute a suicidal response following a 
death stimulus can vary markedly during its differentiation. 
Both positive and negative regulators of apoptosis have 
been identified. The bcl-2 proto-oncogene counters a vari- 
ety of apoptotic stimuli (Vaux et al., 1988; Strasser et al., 
1991; Garcia et al., 1992), indicating that it is a central 
death repressor acting well downstream in this pathway. 
In its gain of function form, CED-9, the homolog of Bcl-2 
in Caenorhabditis elegans, represses the death of all 131 
cells normally destined to die during the development of 
the nematode. Transgenic worms expressing Bcl-2 indi- 
cate that Bcl-2 can substitute for CED-9 in opposing some 
of these deaths (Vaux et al., 1992; Hengartner and Horvitz, 
1994). Thus, evidence exists for an evolutionarily con- 
served cell death pathway that, in its basic tenets, may 
be common to all multicellular organisms. 
An expanding family of Bcl-2-related proteins has re- 
cently been noted to share homology that is principally, but 
not exclusively, clustered within two conserved regions 
entitled Bcl-2 homology domains 1 and 2 (BH1 and BH2) 
(Williams and Smith, 1993; Yin et al., 1994). This includes 
Bax, Bcl-xL, McI-1, A1 (Oltvai et al., 1993; Boise et al., 
1993; Kozopas et al., 1993; Lin et al., 1993), and several 
open reading frames in DNA viruses. Several of these 
have been shown to regulate cell death, including Bcl-xL, 
which represses apoptosis, and its short form Bcl-xs, which 
favors cell death. Bax has been shown to homodimerize 
as well as heterodimerize with Bcl-2. When in excess, Bax 
counters the ability of Bcl-2 to repress cell death (Oltvai 
et al., 1993). Mutagenesis analysis of the BH1 and BH2 
domains in Bcl-2 noted single amino acid substitutions 
that disrupted Bcl-2-Bax heterodimers, but not Bcl-2- 
Bcl-2 homodimers. The Bcl-2 mutants that failed to com- 
plex with Bax could no longer inhibit apoptosis (Yin et al., 
1994). These data argue that this family functions in part 
through protein-protein interactions. 
Analysis of the known Bcl-2 family members in a yeast 
two-hybrid assay demonstrated selective dimerizations. 
Wild-type Bcl-2, but not the BH1 mutants, interacted with 
Bax, validating the yeast assay as being reflective of func- 
tionally significant events in mammalian cells (Sedlak and 
S. J. K., unpublished data). We reasoned that additional 
Bcl-2-interacting proteins might exist that would further 
elucidate the cell death pathway. We utilized Bcl-2 protein 
to screen cDNA libraries in yeast two-hybrid and X expres- 
sion cloning. Both approaches identified the same distant 
bcl-xLIbcl-2-associated death promoter homolog, bad, which 
was conserved within the BH1 and BH2 domains. Bad 
selectively heterodimerizes with Bcl-xL as well as Bcl-2, 
but not with other family members. When Bad heterodi- 
merizes with Bcl-xL in mammalian cells, it displaces Bax 
from Bcl-x, and promotes cell death. This argues that the 
set point of susceptibility to death in such a cell is deter- 
mined by the relative levels and interactions among this 
trilogy of proteins. 
Results 
Isolation of Bad 
The yeast two-hybrid system and X expression cloning 
were used to screen for Bcl-2-interacting proteins. The 
bait plasmid was constructed by fusing Bcl-2, deleted o," 
the C-terminal signal-anchor sequence to ensure translo- 
cation to the nucleus, to the GAL4 DNA-binding domain. 
For a positive control, Bax was fused to the GAL4 activa- 
tion domain. The Bcl-2 bait plasmid was used to screen an 
oligo(dT)-primed mouse embryonic day 14.5 cDNA fusion 
library in a GAL4-activating domain vector (Chevray and 
Nathans, 1992). Transformants (400,000) were screened 
by the X-Gal filter assay. Sequence analysis of cDNA plas- 
raids rescued from 12 positive yeast colonies revealed that 
four plasmids represented two independent clones of the 
same gene. 
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For ~ expression cloning, a GST-Bcl-2 fusion protein con- 
taining a 5 amino acid heart muscle kinase domain (Blanar 
and Rutter, 1992) was in vitro labeled with [7-s~P]ATP and 
was used to screen an oligo(dT)-primed mouse embryonic 
day 16 Ex-lox library (Novagen). Of 750,000 plaques, 12 
positives represented three overlapping clones of the 
same gene isolated from yeast two-hybrid screening. 
bad cDNA and the Protein Sequence It Encodes 
The full-length cDNA sequence was determined from new- 
born mouse brain and adult mouse thymus libraries. The 
gene encodes a previously undescribed protein of 204 
amino acids with a predicted molecular weight of 22.1 kDa. 
We will refer to this gene as bad. Comparison of the Bad 
protein sequence with known Bcl-2 family members re- 
vealed limited homology in the BH1 and BH2 domains 
(Figure 1). Specifically, Bad contains the highly conserved 
and functionally significant W/YGR triplet in BH1, the W 
at position 183, and the WD/E at the conserved exon junc- 
ture in BH2 (Yin et al., 1994). The spacing between the 
conserved BH1 and BH2 domains in Bad is also similar 
to that of the other Bcl-2 homologs. The shortest Bad clone 
that interacted with Bcl-2 possessed the BH1 and BH2 
regions, suggesting that these conserved amino acids 
may be important for binding to Bcl-2 (Figure 1). Unlike 
the other known Bcl-2 family members, Bad does not have 
a predicted C-terminal signal-anchor sequence, suggesting 
that it may not exist as an integral membrane protein. 
Like the Bcl-2 homolog Mci-1, Bad contains two predicted 
PEST sequences flanked by arginine or arginine and histi- 
dine residues (Figure 1) (Rogers et al., 1986). Of note, Bad 
contains a large number of charged residues (25 arginines 
plus lysines, 23 aspartates plus glutamates), with an esti- 
mated isoelectric point of 9.7 and an estimated charge of 
2.47 at neutral pH. PROSITE analysis identified several 
potential phosphorylation and myristoylation sites. BLAST 
searches revealed no further homologies in the existing 
data bases. 
Interaction of Bad with Other Bcl-2 
Family Members 
The full-length badcDNA was cloned into yeast two-hybrid 
vectors and was tested for interaction with the mammalian 
Bcl-2 homologs by both X-Gal filter and liquid ONPG 
assays. Bad interacted strongly with Bcl-x, and Bcl-2 in 
both the DNA-binding domain and activation domain plas- 
mids. Bad did not interact with Bax, Bcl-xs, Mcl-1, or A1. 
Unlike Bcl-2 or Bax, analysis in yeast two-hybrid suggests 
that Bad does not hornodimerize (data not shown). Of note, 
the 1.1 kb bad RNA species is coexpressed with bcl-x~ in 
many tissues (data not shown). 
Bad Heterodimerizes with Bcl-2 and Bcl-x, 
in Mammalian Cells 
An expression plasmid was constructed placing bad, with 
a 9 amino acid hemagglutinin (HA) epitope tag at the 
N-terminus, under the control of the splenic focus-forming 
virus (SFFV) long terminal repeat (Fulbrigge et al., 1988). 
The resultant pSFFVHA-Bad plasmid was stably trans- 
fected into the interleukin-3-dependent (IL-3-dependent) 
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Figure 1. Sequence of Murine bed 
(A) The predicted amino acid sequence of bad. Bold and underlined 
residues are conserved amino acids in BH1 and BH2. Dotted under- 
lined amino acids indicate PEST sequences. Brackets indicate the 
shortest clone identified by Bcl-2 interactive screening. 
(B) Alignment of Bad and Bcl-2 homologs in BH1 and BH2 domains. 
Numbers denote amino acid positions. The most conserved amino 
acids in BH1 and BH2 are stippled. Dashes denote gaps in the se- 
quence to maximize alignment. 
Abbreviations: kD, kilodaltons. 
cell line FL5.12 and into FL5.12 clones already overex- 
pressing Bcl-2 (Nu6ez et al., 1990) or Bcl-x, (Boise et al., 
1993), generating FL5.12HA-Bad clones, FL5.12Bcl-2HA- 
Bad clones, and FL5.12Bcl-x,HA-Bad clones. The expres- 
sion levels of HA-Bad in these clones was determined by 
Western blot analysis using either the monoclonal anti- 
body (MAb) to the HA tag (12CA5) or a novel polyclonal 
antibody to Bad (anti-Bad Ab). While the predicted molecu- 
lar weight of HA-Bad was 23.4 kDa, it migrated at 30 kDa 
in SDS-polyacylamide gel electrophoresis (SDS-PAGE). 
This apparent molecular weight was also noted with bac- 
terially produced protein, indicating that the anomalous 
migration is more likely due to primary structure rather 
than posttranslational modification. The FL5.12Bcl-2HA- 
Bad#4 and FL5.12Bcl-xLHA-Bad#7 clones, which ex- 
pressed comparable amounts of Bad (Figure 2A), were 
analyzed for in vivo heterodimerizations. 
Immunoprecipitation f Bad, Bcl-2, and Bcl-xL were per- 
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Figure 2. Western Blot Analysis and Viability of Bad-Expressing 
FL5.12 Clones 
(A) Protein lysate (75 ~g) was loaded in each lane. The anti-HA MAb 
12CA5 was used to detect HA-Bad. The blot was developed with 
diaminobenzidine. Lane 1, FL5.12Neo; lane 2, FL5.12Bcl-XL; lane 3, 
FL5.12Bcl-xLHA-Bad#7; lane 4, FL5.12Bcl-2; and lane 5, FL5.12Bcl- 
2HA-Bad#4. 
(B) Viability assays. Independent clones indicated by the symbols were 
deprived of IL-3, and the fraction of viable cells (with horizontal bars 
indicating - SEM) was assessed by trypan blue exclusion. Data points 
were obtained from three or more experiments. 
Symbols: open circle, FL5.12Neo; open square, FL5.12Bcl-2; closed cir- 
cle, FL5.12Bcl-2HA-Bad#4; open triangle, FL5.12Bcl-2HA-Bad#15; 
closed triangle, FL5.12Bcl-xLHygro; cross marks, FL5.12Bcl-xLHA- 
Bad#7; closed square, FL5.12Bcl-xLH.~-Bad#8. 
formed with 3sS-labeled cells solubilized in 0.2% Nonidet 
P-40 (NP-40), which permits dimers of the Bcl-2 family to 
remain intact. The MAb to human Bcl-2, 6C8, immunopre- 
cipitated the expected 25 kDa Bcl-2 and its heterodimeriz- 
ing partner Bax from FL5.12Bcl-2 cells (Figure 3A). Immu- 
noprecipitation of lysates from FL5.12Bcl-2HA-Bad#4 
with 6C8 yielded a 30 kDa species in addition to Bcl-2 and 
Bax. The 12CA5 MAb immunoprecipitated the same 30 
kDa band, confirming its identity as HA-Bad (Figure 3A). 
12CA5 also immunoprecipitated a 25 kDa band, which 
proved to be Bcl-2 by Western blot analysis (Figure 3B). 
The anti-Bad polyclonal Ab showed the same immunopre- 
cipitation pattern as 12CA5 (data not shown). Therefore, 
we have demonstrated that Bad and Bcl-2 proteins copre- 
cipitate. Consistent with the yeast two-hybrid data that 
predicted the absence of Bad-Bax  dimers, no Bax band 
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Figure 3. Coimmunoprecipitation f Bcl-2 and Bad 
(A) Primary immunoprecipitation f the 3sS-labeled FL5.12Bcl-2 line 
(lanes 2, 3, 4) and FL5.12Bcl-2 transfected with pSFFVHA-Bad#4 
(lanes 5, 6, 7). 6C8 is a MAb specific for human Bcl-2, and 120A5 is 
a MAb against he HA epitope. One half of each sample was loaded 
on a 12.5% SDS-PAGE gel and fluorographed. 
Abbreviations: C, isotype control Ab; KD, kilodaltons; M, marker lane. 
(B) One half of each sample from (A) was used in Western blotting 
with 608 MAb and was developed with enhanced chemiluminescence. 
Abbreviations: KD or kD, kilodaltcns. 
(C) Shown here is primary (1 °) immunoprecipitation of 35S-labeled 
FL5.12Bcl-2HA-Bad#4 with 6C8 (lane 2) and secondary (2 °) immune- 
precipitation of that supernatant with anti-Bad Ab (lane 3). 
Abbreviation: kD, kilodaltons. 
was immunoprecipitated with HA-Bad in the 12CA5 lane. 
This also demonstrates that Bcl-2, which is bound to HA-  
Bad, is not heterodimerized with Bax. Thus, there is no 
evidence for the presence of Bad-Bc l -2 -Bax hetero- 
trimers. 
A parallel series of immunoprecipitations was performed 
on FL5.12Bcl-xLHA-Bad clones using an anti-Bcl-x poly- 
clonal Ab. In FL5.12Bcl-XL cells, anti-Bcl-x Ab captured the 
28 kDa Bcl-XL protein and a 21 kDa protein that has been 
proven to be Bax (Figure 4A) (Sedlak and S. J. K., unpub- 
lished data). In FL5.12Bcl-xLHA-Bad#7 lysates, anti-Bcl-x 
Ab precipitated Bcl-XL and a 30 kDa species consistent 
with HA-Bad,  the identity of which was confirmed on a 
Western blot using anti-Bad Ab (Figure 4C). Similarly, in 
addition to the 30 kDa HA-Bad,  both 12CA5 MAb and 
anti-Bad Ab precipitated a 28 kDa species, which was con- 
firmed to be Bcl-XL on immunoblott ing (Figure 4B). Thus, 
HA-Bad and Bcl-XL proteins coprecipitate. Again, the Bcl-XL 
molecules that are bound to Bad are not heterodimerized 
with Bax. Moreover, in the anti-Bcl-x immunoprecipitate 
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Figure 4. Coimmunoprecipitation of Bcl-XL and Bad 
(A) Primary immunoprecipitation of the 3sS-labeled FL5.12Bcl-XL line 
(lanes 2, 3, 4) and one of the pSFFVHA-Bad transfected clones (lanes 
5, 6, 7) using anti-Bcl-x Ab, 12CA5, and anti-Bad Ab. One third of each 
sample was loaded on a 12.5% SDS-PAGE gel and fluorographed. 
(B) Western blotting of one third of each primary immunoprecipitate 
using biotinylated anti-Bcl-x Ab, developed with diaminobenzidine. 
(C) Western blot of one third of each primary immunoprecipitate using 
biotinylated anti-Bad Ab, developed with diaminobenzidine. 
(D) Shown here is primary (1 °) immunoprecipitation of 3sS-labeled 
FL5.12Bcl-xLHA-Bad#7 with anti-Bcl-x (lane 2) and secondary immu- 
noprecipitation f that supernatant with 12CA5 (lane 3). 
Abbreviation: M, marker lane. 
of FL5.12Bcl-xLHA-Bad#7, little or no Bax is present, indi- 
cating that nearly all of the Bcl-XL is dimerized with HA- 
Bad (Figure 4A). 
To assess further the xtent o which HA-Bad had com- 
plexed with Bcl-2 or Bcl-XL, secondary immunoprecipita- 
tions were performed on the supernatants of the aforemen- 
tioned experiments. In FL5.12Bcl-2HA-Bad#4 cells, the 
intensity of Bcl-2 to HA-Bad bands in the primary 6C8 
immunoprecipitates showed a ratio of -2:1 by phos- 
phorimager scanning. When the supernatant of this Bcl-2- 
depleted immunoprecipitate was reprecipitated with anti- 
Bad Ab, a reversed ratio of Bcl-2 to HA-Bad of - 1:3 was 
noted (see Figure 3C), indicating that excess Bad, not 
heterodimerized with Bcl-2, existed. However, a parallel 
experiment with FL5.12Bcl-xLHA-Bad#7 cells revealed a 
Bcl-XL to HA-Bad ratio of - 1:1 in primary anti-Bcl-x im- 
munoprecipitates. When the supernatant of this Bcl-XL-- 
depleted immunoprecipitate was reprecipitated with anti- 
Bad Ab or 12CA5, only small amounts of residual Bcl-XL 
and HA-Bad were detected at a -1:1 ratio (Figure 4D), 
consistent with these proteins being complexed as hetero- 
dimers. In FL5.12Bcl-xLHA-Bad#7 cells, nearly all the Bcl- 
XL is heterodimerized with HA-Bad, and virtually none is 
heterodimerized with Bax (Figure 4A). In FL5.12Bcl-2HA- 
Bad#4 cells, despite an excess of HA-Bad, a substantial 
fraction of Bcl-2 is still heterodimerized with endogenous 
Bax (see Figure 3A). These data are consistent with a 
stronger association between Bcl-XL and Bad than that 
between Bcl-2 and Bad. 
Bad Counters the Death Inhibition by Bcl-x,, 
but Not That by Bcl-2 
Both Bcl-2 and Bcl-x, function as death repressors, ex- 
tending the viability of FL5.12 cells following IL-3 with- 
drawal (Hockenbery et al., 1990; Boise et al., 1993). The 
viability curves of the six FL5.12HA-Bad clones deprived 
of IL-3 were not convincingly different from those of 
FL5.12Neo control lines (data not shown), indicating that 
overexpressed Bad by itself did not affect apoptosis in this 
cell line. In addition, the survival curves for two indepen- 
dent Bcl-2- and Bad-overexpressing clones, FL5.12Bcl- 
2HA-Bad#4 and -#15, did not vary significantly from that 
of FL5.12Bcl-2 cells (see Figure 2B), showing that Bad 
had no substantial effect on the death repressor function 
of Bcl-2. In contrast, the viability of clones coexpressing 
Bcl-XL and Bad proved significantly different from that 
of FL5.12Bcl-XL cells. FL5.12Bcl-xLHA--Bad#7 clone ex- 
pressed a high level of Bad and exhibited a viability that 
nearly reverted to the pattern of several FL5.12Neo control 
lines (see Figure 2B). FL5.12Bcl-xLHA-Bad#8 expressed 
a low amount of Bad protein (Figure 5A) and showed a 
slightly diminished viability compared with FL5.12Bcl-xL 
upon IL-3 withdrawal (see Figure 2B). Therefore, at similar 
levels of expression (see Figure 2A), Bad countered the 
death repressor activity of Bcl-xL, but not that of Bcl-2, 
in this death assay. Immunoprecipitations u ing mouse 
thymocytes revealed an association of endogenous Bcl-XL 
and Bad in vivo (data not shown), arguing that this interac- 
tion will be relevant in normal cells. 
Bad Successfully Competes for Bcl-x,, 
Resulting in Free Bax 
The differential effectiveness of Bad in countering Bcl-x, 
but not Bcl-2 activity may be explained by the observation 
that more of the available Bad is bound to Bcl-xL than to 
Bcl-2 (see Figures 3 and 4). Since heterotrimers do not 
appear to exist, this implies that the amount of Bax that 
is"unbound", that is, not heterodimerized toBcl-x, or Bcl-2, 
would be affected by the presence of Bad. To test this 
hypothesis, the amount of Bax not involved in Bcl-xL-Bax 
or Bcl-2-Bax heterodimers was determined. Sequential 
immunoprecipitations were performed in the following 
manner: primary immunoprecipitations were performed 
on 35S-labeled FL5.12Bcl-xLHA-Bad and FL5.12Bcl-2HA- 
Bad clones in 0.2% NP-40 using either anti-Bcl-x Ab or 
6C8, respectively (Figure 5A); the supernatants were 
cleared a second time with these antibodies to remove 
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Figure 5. The Amount of Bax Not Found in Heterodimers Correlates 
with Cell Death 
Sequential immunoprecipitations were performed on the clones indi- 
cated above the lanes. 
(A) Using half of the 3~S-labeled cells from each clone, anti-Bcl-x was 
incubated with 0.2% NP-40 lysates of clones expressing Bcl-xL, and 
6C8 was incubated with those expressing human Bcl-2. Primary immu- 
noprecipitates were separated on 12.5% SDS-PAGE gels and fluoro- 
graphed. 
(B) Immunoprecipitation of Bax from supernatants from the cells in 
(A). The supernatants from (A) were cleared a second time with the 
same Ab to remove all Bcl-xL and Bcl-2 complexes. These doubly 
cleared supernatants were incubated with the 4D2 anti-Bax MAb and 
were electrophoresed on 12.5% SDS-PAGE gels to quantitate the 
amount of Bax not complexed with either BCI-xL or Bcl-2. 
(C) The other half of the 3~S-labeled cells was lysed in radioimmunopre- 
cipitation assay buffer and was imm unoprecipitated with 4D2 to quanti- 
tate the total amount of Bax. Bands were quantitated by a phosphorim- 
ager. The fraction of Bax not in heterodimers with 8cl-xL or Bcl-2 was 
determined inthree experiments, and the average value is shown. 
Abbreviations: kD, kilodaltons; M, marker lane. 
all Bcl-XL or Bcl-2 complexes; finally, these heterodimer- 
depleted supernatants were immunoprecipitated with the 
MAb anti-Bax, 4D2 (Figure 5B). One half of the original 
35S-labeled cells were lysed in radioimmunoprecipitation 
assay buffer, which disrupts dimers of this family, and were 
immunoprecipitated with 4D2 to establish the total amount 
of cellular Bax in each preparation (Figure 5C). The amount 
of Bax present in each precipitation was quantitated by 
phosphorimager scanning. This experiment was per- 
formed three times, and the average value for the fraction 
of Bax not found in heterodimers is presented (Figure 5). 
In FL5.12Neo control cells, most of the Bax (97o), pre- 
sumably present as homodimers, was not heterodimer- 
ized, as shown previously (Oltvai et al., 1993). The primary 
immunoprecipitation with 6C8 and anti-Bcl-x confirmed 
the persistence of Bcl-2-Bax heterodimers in FL5.12Bcl- 
2HA-Bad#4 and Bcl-XL-Bax heterodimers in FL5.12Bcl- 
XLHA-Bad#8 but not in FL5.12Bcl-xLHA-Bad#7 (Figure 
5A). Reciprocally, the amount of Bad in Bcl-XL-Bad hetero- 
dimers in clone #7 is greater than the amount of Bad in 
Bcl-2-Bad heterodimers in clone #4 (Figure 5A). This re- 
sulted in a marked difference in the fraction of Bax not 
present in heterodimers. In FL5.12Bcl-XL and FL5.12Bcl-2 
cells that are protected from apoptosis, half or less of the 
total Bax was not heterodimerized (52% and 39%, respec- 
tively). In FL5.12Bcl-xLHA-Bad#7 cells that have regained 
susceptibility to death, as much as 79% of the total Bax 
was not complexed to Bcl-XL. In contrast, in FL5.12Bcl- 
xLHA-Bad#8 and FL5.12Bcl-2HA-Bad#4, which still re- 
tained considerable protection, the percent of "free" Bax, 
that not found in heterodimers with Bcl-XL or Bcl-2, was 
53% and 47%, respectively (Figure 5). 
Discussion 
Both yeast two-hybrid and ;L expression cloning experi- 
ments identified the same novel Bcl-2 family member, 
Bad. This protein qualifies for Bcl-2 family membership in 
that it possesses the key amino acid motifs of BH1 and 
BH2 domains, and a small region of Bad containing BH1 
and BH2 binds Bcl-2. However, outside BH1 and BH2, 
Bad is quite distinct from other members. Moreover, Bad 
lacks the classic C-terminal signal-anchor sequence re- 
sponsible for the integral membrane position of other fam- 
ily members. Bcl-2 has been localized to the mitochondrial 
membrane, endoplasmic reticulum, and nuclear mem- 
brane (Hockenbery et al., 1990; Monaghan et al., 1992; 
de Jong et al., 1994), and Bcl-XL has been im munolocalized 
to the outer mitochondrial membrane (Gonz&lez-Garda et 
al., 1994). In vitro targeting studies have demonstrated 
that the C-terminal tail of Bcl-2 serves as a signal-anchor 
sequence capable of integrating into a variety of mem- 
branes (Nguyen et al., 1993). Protease digestions confirm 
that the majority, ifnot all, of Bcl-2 has its N-terminus facing 
the cytosol. Thus, Bcl-2 or Bcl-XL could be expected to 
interact with a predicted cytosolic protein such as Bad. It is 
possible that Bad could communicate with other cytosolic 
proteins connecting the genetic pathway of cell death with 
other cellular processes. 
Yeast two-hybrid analysis indicated that Bad would in- 
teract with Bcl-XL as well as with Bcl-2. Immunoprecipita- 
tions in mammalian cells confirmed this prediction. The 
data favor a model of simple dimers in which Bad com- 
petes with Bax for association with Bcl-2 or Bcl-XL. There 
was no evidence for the existence of any heterotrimers. 
The binding of Bad appeared to preclude the binding of 
Bax to either Bcl-XL or Bcl-2. In cells with abundant Bcl-XL- 
Bad heterodimers, no Bcl-XL-Bax heterodimers were pres- 
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ent. In Bcl-2-expressing cells, less Bcl-2 is complexed with 
Bad, and Bcl -2-Bax heterodimers were still present. This 
suggested that Bad has a higher affinity for Bcl-XL than 
for Bcl-2, although unanticipated ifferences in the subcel- 
lular availabil ity of each protein could also affect these 
findings. 
Cell death assays corroborated the significance of Bad 
heterodimerizations. Bad itself probably does not function 
as a singular, downstream death effector molecule be- 
cause, when expressed by itself, it had no effect upon the 
death course of FL5.12 cells deprived of IL-3. FL5.12 cells 
express little Bcl-2, no detectable Bcl-XL, and abundant 
Bax protein. In these cells, Bad countered the death inhibi- 
tion by Bcl-x, much more than it countered that by Bcl-2. 
This correlated with the proclivity of Bad to heterodimerize 
with Bcl-x, more than it heterodimerized with Bcl-2. 
Recently, Bcl-XL has been shown to heterodimerize with 
Bax in mammal ian cells as well as in yeast two-hybrid 
cells. A WAR for WGR substitution of the critical glycine 
in the BH1 domain was generated for Bcl-XL. Parallel to 
this mutation in Bcl-2, this Bcl-XL ml-3 protein no longer 
heterodimerized with Bax and also lost its death repressor 
activity (Sedlak and S. J. K., unpublished data). This pro- 
vides further evidence for a model in which both Bcl-XL 
and Bcl-2 must dimerize with Bax to repress death. The 
data with Bad further support this thesis and adds a third 
layer of complexity. Overall, the data argue for a simple 
competit ion in which Bad binds Bcl-XL, displacing Bax into 
homodimers. Susceptibil ity to cell death is best correlated 
with the percent of Bax in heterodimers versus that in 
homodimers. If roughly half of Bax is complexed in hetero- 
dimers, FL5.12 cells will be protected from death. For- 
mally, it is not certain whether Bax-Bax  homodimers are 
the active moiety that might communicate with a death 
effector pathway or whether each Bcl -2-Bax or Bcl-XL- 
Bax heterodimer is the active component. 
The Bcl-XL, Bax, and Bad system is reminiscent of the 
Myc, Max, and Mad regulatory network of basic helix-loop- 
helix transcription factors (Amati et al., 1993; Ayer et al., 
1993). Myc-Max  and Mad-Max heterodimers display pos- 
itive and negative regulation of transcription, respectively. 
Myc and Mad both compete for binding to Max, and their 
relative levels determine the dominant heterodimer. Mad 
displays several characteristics parallel to Bad in that Mad 
is also a modulatory protein that does not regulate tran- 
scription by itself, but functions by sequestering Max in 
complexes that prevent it from binding Myc to activate 
transcription. In a parallel fashion, Bad is a regulator of 
apoptosis that appears to function by sequestering Bcl-x, 
and by preventing Bcl-xL from heterodimerizing with Bax. 
The susceptibil ity to cell death is dictated by a complex 
set point determined by the relative levels and interactions 
of Bcl-XL, Bcl-2, Bax, and Bad proteins. The presence of 
the novel protein, Bad, is one regulator that can determine 
whether the Bcl-2 or the Bcl-x, molecule will be effective 
in repressing apoptosis. 
Experimental Procedures 
Plaemid Constructions 
Standard PCR reactions were used to construct yeast fusion plasmids. 
The amino acids in the C-terminal transmembrane segments were 
deleted as follows: 21 amino acids were deleted from muScl-2, 18 
from muBax, 19 from huBcl-XL, 19 from huBcl-xs, 21 from muMcl-1, 
and 21 from muAl. 
The expression plasmid pSFFVHA-Bad was constructed by using 
PCR primers, which incorporated the 9 codons of the HA epitope (Ko- 
Iodziej and Young, 1991) onto the 5' end of bad, and it was ligated 
into pSFFV vector at the EcoRI site. 
Strains and Cell Lines 
The yeast strains used in the yeast two-hybrid screening were PCY2 
(Chevray and Nathans, 1992) and Y 190 (MA Ta gal4 gal80 his3 trp 1-901 
ade2-101 ura3-52 leu2-3,-112 URA 3: :GAL-/acZ L YS : :GAL-H IS3 cyhr). 
Yeast transformations were done using the standard lithium acetate 
procedure. 
The FL5.12 cell line and its derivatives were cultured as previously 
described (McKearn et aL, 1985). 
Yeast Two-Hybrid Screening 
PCY2 harboring the GAL4 DNA-binding domain Bcl-2 plasmid was 
transformed with 4 I~g of an oligo(dT)-primed mouse 14.5 day embryo 
fusion cDNA library constructed in the GAL4-activating domain vector. 
Transformants were plated on -Leu -Trp medium and were screened 
by the filter X-Gal assay (Chevray and Nathans, 1992). Blue colonies 
cured of the bait plasmid were mated to Y190 carrying either vector 
alone or nonspecific bait plasmids, and the rescued cDNA plasmids 
were cotransformed back into PCY2 with irrelevant bait plasmids so 
as to identify those cDNA isolates that were specifically positive with 
Bcl-2. 
Expression Cloning 
Bacterially produced GST-HMK-Bcl-2AC21 was purified, labeled, 
and used to screen phage filters in 0.05% NP-40 and 1 mM D'I-F, 
according to the protocol of Blanar and Rutter (1992). 
cDNA Screening 
A bad coding region probe was used to screen 1 x 106 plaques each 
of a newborn mouse brain and an adult mouse thymus ZZAPII cDNA 
library. Standard phage screening techniques were employed. 
Transfections 
FL5.12 cells were electroporated at 200 V and 900 p_F. Later (48 hr), 
the cells were plated at limiting dilution in medium containing 1 mg/ 
ml G418 in 96-well microtiter dishes. Single-cell origin clones were 
picked 10-14 days later. 
Antibodies 
6C8 is a human Bcl-2-specific hamster MAb (Hockenbery et al., 1990). 
12CA5 is a murine MAb against influenzavirus HA protein epitope. 4D2 
is a hamster MAb against mudne Bax (Sedlak and S. J. K., unpublished 
data). Anti-Bcl-x Ab is a polyclonal Ab against Bcl-x. The rabbit poly- 
clonal anti-Bad Ab was raised against bacterially produced protein 
and was protein A purified. For immunoprecipitations, 6C8 was used 
at a final concentration of 20 p_g/ml, 12CA5 was used at 40 i~g/ml, 
anti-Bcl-x Ab was used at 10 p.I per 1 x 107 cells. 4D2 and anti-Bad 
Ab were titrated to be maximally efficient at 48 i~g/ml and 60 ~g/ml. 
Western Blotting Analysis 
Cells were lysed in 100 mM Tris (pH 7.5), 75 mM NaCI, 1% Triton 
X-100, 1% PMSF, and 1% aprotinin. Standard Western blotting proce- 
dures were employed. Abs were incubated for 1 hr at room tempera- 
ture. 12CA5 MAb supernatant was used at 1:50 dilution, anti-Bcl-x Ab 
was used at 1:1000, anti-Bad Ab was used at 1:1000, and 6C8 was 
used at 1:100. Biotinylated secondary goat Ab (Caltag) was used at 
1:500, and horseradish peroxidase-conjugated streptavidin (Zymed) 
was used at 1:1000 when developed with diaminobenzidine and at 
1:20,000 when developed with ECL. 
Immunoprecipitations 
Each immunoprecipitation used 1 x 107 cells labeled in methionine- 
free Dulbecco's modified Eagle's medium, 10O/o dialyzed fetal calf se- 
rum, 10O/o WEHI-3B supernatant, and 100 i~Ci of Tran35S-label for 12 
hr. Subsequent steps were carried out as previously described (Oltvai 
et al., 1993). ~S-labeled bands were quantitated by phosphorimager 
scanning. 
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